NasdaqGS:RGENLife Sciences
Repligen (RGEN) Stock Faces A Margin Puzzle After Revenue Growth
Repligen stock was up more than 28% over the past three months coming into this report. Today it slipped about 2% in midday trade. That modest pullback sits awkwardly against what the quarter actually showed. Revenue reached about US$204.1m and organic growth hit 13%. Adjusted gross margin expanded to roughly 53.9% and adjusted operating margin moved to 16.7%, pointing to margin strength rather than strain.
If you own Repligen you are not trading a missed quarter. You are trading how much...